
X
Alnylam files its third RNAi drug lumasiran in rare kidney disease
https://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/
Advance Therapeutics for Chronic Kidney Diseases
Advance Therapeutics for Chronic Kidney Disease
After manufacturing issues, AstraZeneca hopes for FDA nod soon.
Deal is result of six-year collaboration with AZ
Soliris fails when used to treat post-transplant complications.